Turkey's Social Security Institution (SGK), Genel Sağlık Sigortası Genel Müdürlüğü, published Announcement 2026/31 on August 12, 2026, amending the Bedeli Ödenecek İlaçlar Listesi (List of Reimbursable Pharmaceuticals, EK-4/A). Under Article 12 of the SGK Drug Reimbursement Regulation and SUT Articles 4.4.1 and 4.4.2, the changes take effect on August 14, 2026.
The package adds one product, revises three listed lines, passivates one product, and removes four products from EK-4/A. For marketing authorisation holders and distributors selling into Turkey, SUT listing remains the gate to real market access: products off the reimbursable list lose public reimbursement coverage from the effective date.
What exactly changed in Announcement 2026/31?
The official PDF announcement and the accompanying EK-4/A Excel workbook structure the amendment in four annexes.
Added (EK-1): DOLUSEV 50 mg film-coated tablet (Kamu No A20333, barcode 8680760093119), equivalent group E999A, applied discount rate 0.28, list entry date August 14, 2026.
Amended (EK-2): NOVOEIGHT 3000 IU powder and solvent for solution for injection (A20168), TIVICAY 50 mg 30 film-coated tablets (A14984), and TRAJENTA 5 mg film-coated tablet (A15827). Each row carries an updated discount category (blood product for NovoEight; reference for Tivicay and Trajenta) at rate 0.11 or 0.28.
Passivated (EK-3): NETOLP 150 mg film-coated tablet (A20237, barcode 8680352000259), passivation date August 14, 2026.
Removed (EK-4): PREDNI-POS 1% 10 ml ophthalmic suspension (A10293), SICCAPOS 0.2% 10 g eye gel (A07229), SICCAPROTECT 10 ml eye drops (A07230), and 1/4 ISODEXOL 500 ml solution with IE set (A00295).
| Annex | Action | Products (Kamu No) | Effective |
|---|---|---|---|
| EK-1 | Added | DOLUSEV 50 mg (A20333) | August 14, 2026 |
| EK-2 | Amended | NOVOEIGHT 3000 IU (A20168); TIVICAY 50 mg (A14984); TRAJENTA 5 mg (A15827) | August 14, 2026 |
| EK-3 | Passivated | NETOLP 150 mg (A20237) | August 14, 2026 |
| EK-4 | Removed | PREDNI-POS (A10293); SICCAPOS (A07229); SICCAPROTECT (A07230); 1/4 ISODEXOL (A00295) | August 14, 2026 |
Who is hit, and what does passivation versus removal mean operationally?
Every MAH with a product on or seeking EK-4/A listing, plus wholesale distributors (Selçuk Ecza, Hedef, Allianz Ecza and peers) and healthcare providers billing SGK, must reconcile their SKRS / MEDULA coding against this workbook before claims on or after August 14, 2026.
Passivation of NETOLP stops active reimbursement for that barcode while the Kamu No remains on the historic list; removal of the four ophthalmic and infusion lines means those barcodes leave EK-4/A entirely. Amended lines (NovoEight, Tivicay, Trajenta) keep reimbursement but under the revised equivalent-group / discount parameters published in EK-2. Newly added DOLUSEV becomes reimbursable from the same date, subject to the E999A equivalent-group and 0.28 discount rules.
Under the Turkish pricing and reimbursement split, TİTCK still owns marketing authorisation; the MoH-coordinated Pricing Evaluation Commission owns list price; SGK alone decides what the public payer reimburses. No SUT / EK-4/A listing means no real market access for the SSI-insured population.
What must market-access and supply teams do by August 14, 2026?
Treat August 14, 2026 as an operational cut-over, not a consultation milestone. Map every SKU in Turkey portfolios to the four annexes; quarantine passivated and removed barcodes from SSI claim pipelines; push the DOLUSEV addition and the three EK-2 parameter changes into pricing, tender and hospital formulary feeds the same day.
Confirm with local affiliates and depots that MEDULA / hospital systems will reject claims for NETOLP and the four removed products from August 14, 2026, and that NovoEight, Tivicay and Trajenta invoices use the updated discount categories. Brief hospital and retail pharmacy partners on the ophthalmic removals so stock and substitution protocols are updated before the first claim cycle after the cut-over.
Continuous, per-jurisdiction monitoring is how teams catch SGK list amendments of this type the day they publish, rather than after the first rejected claim.
How does this sit in Turkey's recurring SUT list cycle?
Announcement 2026/31 is the 31st SGK reimbursable-list update of 2026: a recurring binding instrument, not a one-off statute. TEDK and the Pharmaceutical Reimbursement Committee feed these list decisions; SGK Presidency publishes them as numbered duyurular with annex workbooks. Application windows for new reimbursement dossiers remain the end-of-March and end-of-July cycles under the Drug Reimbursement Regulation; this announcement is the downstream list publication that those evaluations produce.
Contact for the package sits with Genel Sağlık Sigortası Genel Müdürlüğü / İlaç Daire Başkanlığı ([email protected]). For products not named here, the status quo on EK-4/A continues unchanged.
Take advantage of this real-time watch
Next steps: download the PDF and Excel from the SGK duyuru, reconcile every Turkey SKU against the four annexes before August 14, 2026, update claim and formulary systems for additions, amendments, passivations and removals, and brief market-access and supply leads. Obsidian tracks these SGK list publications as they land so the next numbered duyuru does not arrive as a surprise claim rejection.
